Nuttall I D, Elstein M, McCafferty E, Seth J, Cameron E D
Contraception. 1982 Aug;26(2):121-35. doi: 10.1016/0010-7824(82)90081-6.
A new combined pill containing 20 micrograms of ethinyl estradiol and 250 micrograms of levonorgestrel has been developed. The safety margin of this type of low-dose preparation needed to be assessed and this was done by evaluating daily levels of LH, FSH, estradiol, progesterone, 1-NG and EE2 as well as cervical mucus characteristics in six patients when one and then two consecutive pills were deliberately omitted mid-way through the cycle. Results demonstrated that there was no evidence of breakthrough ovulation, although there was some continued ovarian steroidogenesis, a feature consistent with previous studies using combined preparations. Existing instructions to patients regarding missed pills should continue in order to ensure maximal contraceptive safety.
一种含有20微克炔雌醇和250微克左炔诺孕酮的新型复方避孕药已研制成功。需要评估这类低剂量制剂的安全范围，通过在六名患者的月经周期中途故意漏服一片然后连续漏服两片时，评估促黄体生成素（LH）、促卵泡生成素（FSH）、雌二醇、孕酮、1-去甲诺孕烯（1-NG）和炔雌醇（EE2）的每日水平以及宫颈黏液特征来进行评估。结果表明，虽然存在一些持续的卵巢甾体生成，但没有突破性排卵的证据，这一特征与先前使用复方制剂的研究一致。为确保最大程度的避孕安全性，应继续沿用现有的给患者关于漏服避孕药的说明。
